Pituitary gigantism
ICD-10 E22.0 · ICD-11 5A60.0.1

Pituitary Gigantism with Modestly Elevated Serum IGF-1 and Mild Clinical Signs of Acromegaly

Clinical Scenario

This protocol targets patients with pituitary gigantism whose serum IGF-1 is modestly — rather than markedly — elevated, and whose clinical signs and symptoms of acromegaly remain mild.

Modestly elevated serum IGF-1 together with mild acromegaly manifestations characterises this sub-population and directly informs the initial treatment selection.

Treatment Goals

The primary biochemical targets are an age-normalised serum IGF-1 value and a random growth hormone level below 1.0 µg/L, consistent with established guidelines for acromegaly management.

Therapeutic Approach

In this setting, a dopamine agonist may be appropriate as initial adjuvant medical therapy. The full protocol details which agent is preferred, the selection criteria, monitoring approach, and what to do if targets are not reached.

Complete regimen available via the link below.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/B978-0-12-814537-1.00002-6

Those with modestly elevated serum IGF-1 and mild clinical signs/symptoms of acromegaly, could receive a dopamine agonist, usually cabergoline, as initial adjuvant medical therapy.

According to the 2014 Guidelines from the Endocrine Society, the main biochemical goals for treatment of acromegaly are an age-normalized serum IGF-1 value (disease control), a random GH < 1.0 µg/L (correlates with disease control), and to use the same hormonal assays throughout management.

View source ↗